US20080299556A2

US20080299556A2 - Alkylguanyltransferase Assays

Info

Publication number: US20080299556A2
Application number: US11/856,909
Authority: US
Inventors: Ivan King; Xu Lin
Original assignee: Vion Pharmaceuticals Inc
Current assignee: Vion Pharmaceuticals Inc
Priority date: 2005-03-11
Filing date: 2007-09-18
Publication date: 2008-12-04
Also published as: US20060205027A1; US7273714B2; US20080076132A1

Abstract

This invention provides a method to determine alkylguanyltransferase activity in a sample, comprising steps of placing the sample in an appropriate condition so that the AGT is functional; contacting the sample with an AGT Detector under conditions permitting the binding of AGT and AGTD to produce a signal; and measuring the signal, thereby determining the AGT activity in said sample. This invention provides different uses of this method.

Description

This application is a continuation of U.S. Ser. No. 11/373,623, filed Mar. 9, 2006, now U.S. Pat. No. 7,273,714, issued Sep. 25, 2007, which claims the benefit of U.S. Ser. No. 60/663,454, filed Mar. 18, 2005 and U.S. Ser. No. 60/660,738, filed Mar. 11, 2005. The contents the preceding applications are hereby incorporated herein by reference in their entireties.
Throughout this application, various references are referred to and disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

Chemotherapeutic agents that alkylate the O⁶position of guanine in DNA such as Carmustine (Ishibashi, et al., J. Biol. Chem., 269: 7645-7650, 1994) 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, fotemustine, dacarbazine, streptozotocin, procarbazine, and temozolomide (TMZ) are used primarily to treat brain cancer, melanoma, lymphoma, and gastrointestinal cancers. The effectiveness of these agents, however, is limited by alkylguanyltransferase (AGT), a protein that repairs O⁶-alkylguanine adducts and is up-regulated in several tumors during progression (Ishibashi et al., Mutat. Res., 315: 199-212, 1994; Citron et al., Cancer Investig., 12: 605-610, 1994; Kokkinakis et al., Cancer Res., 57: 5360-5368, 1997).
Furthermore, selection of resistant AGT phenotypic populations after treatment with alkylating agents seems to be the reason for the recurrence of tumors of even a more resistant phenotype (Lage et al., J. Cancer Res. Clin. Oncol., 125: 156-165, 1999). Tumor resistance to DNA alkylation could be theoretically reversed with AGT inhibitors that react with and inactivate the protein. Despite considerable advances in this field, methodologies to sensitize tumors by depleting AGT and the selection of the appropriate chemotherapeutic agent to be combined with AGT depleting drugs are still under evaluation.
An additional important issue in combining DNA alkylating agents with AGT inhibitors is whether to include such inhibitors in the treatment of tumors with no or low AGT content, especially because such a combination limits the dose of the alkylating agent. Dose is important for several reasons, including the fact that the alkylating agent itself might quench low levels of AGT. A case in point is TMZ, which at a dose of 100 mg/kg eliminates all of the AGT activity in tumors having moderate AGT levels for a prolonged time period (Chinnasamy et al., Blood, 89: 1566-1573, 1997). In addition, the inverse correlation between AGT levels and effectiveness of BCNU against central nervous system tumors (Belanisch et al., Cancer Res., 56: 783-788, 1996; Jaeckle et al., J. Clin. Oncol., 16: 3310-3315, 1998) suggest that there may be no benefit in treating AGT-deficient tumors with AGT inhibitors. Determining the threshold of AGT activity that could be overcome by alkylating agents without the use of AGT inhibitors may be beneficial.
High AGT activity confers resistance to DNA alkyating agents (see above). A sensitive and fast turn-round AGT assay could be used to select patients with low AGT activities, and thus provide a better outcome for patients receiving DNA alkylating agents. A few assays have been developed but they are either not sensitive enough or so labor-intensive that they are not suitable for routine laboratory use (Wu et al., Cancer Res., 47: 6229, 1987; Gerson et al., J. clin. Invest., 76:2106, 1985; Kreklau et al., Nucleic Acid Res., 29:2558, 2001).
This invention provides an improved assay, which is simple and efficient, for alkylguanyltransferase.

SUMMARY OF THE INVENTION

This invention provides a method to determine alkylguanyltransferase (AGT) activity in a sample, comprising steps of:

- (a) placing the sample in an appropriate condition so that the AGT is functional;
- (b) contacting the sample with an alkylguanyltransferase detector (AGTD) under conditions permitting the binding of AGT and AGTD to produce a signal; and
- (c) measuring the signal, thereby determining the AGT activity in said sample.

This invention provides an AGTD which contains:

- (a) a AGT binder; and
- (b) a detectable signal; and optionally,
- (c) a system that detect the signal which subsequently generates a second signal.

The first or second signal, in the form of color, light, fluorescence, or radioactivity, is then detected with the corresponding methods.
Finally, this invention provides different uses of the above method.

DETAILED DESCRIPTION OF THE FIGURES

FIG. 1. Detection of AGT activity
FIG. 2. Signal molecule conjugated to EX
FIG. 3. Signal molecule conjugated to AP
FIG. 4. Signal molecule conjugated to O6BG
FIG. 5. Scintillation Proximity Assay

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method to determine AGT activity in a sample, comprising steps of:

- (a) placing the sample in an appropriate condition so that the AGT is functional;
- (b) contacting the sample with an AGTD under conditions permitting the binding of AGT and AGTD to produce a signal; and
- (c) measuring the signal, thereby determining the AGT activity in said sample.

In an embodiment, the sample is from a patient. As used herein, AGTD comprises:

- (a) a AGT binder;
- (b) a detectable signal; and optionally,
- (c) a system that detect the signal which subsequently generates a second signal.

AGTD may carry more than one signal. The signal may be detected directly or indirectly. For indirect detection, other agent(s) may be used to facilitate said detection. For example, the detectable signal may include an antibody which would be recognized by a second antibody. The second antibody is linked to a marker which is detected by standard methods.
The current assay employs an agent (AGT binder) that binds to AGT, which is capable of transferring a chemical moiety from the AGT binder to AGT. The AGT binder can be an agonist, antagonist, activator, or inhibitor of AGT. These agents include but not limit to N¹, O⁶-ethanoxanthosine (EX) (Noll and Clarke, Nucleic Acid Res., 29: 4025, 2001), 2′-deoxy-6-(cystamine)-2-aminopurine (AP) (Paalman et al., Nucleic Acid Res., 25:1795, 1997), temozolomide, benzylguinine, O(6)-Benzylguanine (O6BG), 8-aza-O(6)-benzylguanine, O(6)-(4-bromophenyl)-guanine (O6BTG), O(6)alkylguanine, and analogues of these agents. AGT binder also includes DNA or oligoribonucleotide or oligodeoxyribonucleotide (collectively called oligonucleotide) containing the above agents.
In one embodiment, the chemical moiety transferred from AGT binder to AGT contains a signal such as radioactivity, fluorescence, luminescence, or electro-spin resonance (ESR). The signal transferred from AGT binder to AGT is directly determined by various methods according to the signal transferred. In another embodiment, the chemical moiety transferred to AGT is indirectly detected with an immunoassay or other affinity binding assay (FIG. 1).
The AGT binder includes an inhibitor or activator of AGT. In an embodiment, the AGT binder is EX and the AGTD is biotin-conjugated EX (FIG. 2). In another embodiment, the AGT binder is AP and the AGTD is biotin-conjugated AP (FIG. 3). In yet other embodiment, the AGT binder is 06BG and the AGTD is biotin-conjugated 06BG (FIG. 4).
In a separable embodiment, the detectable signal molecule is a fluorophore.
The invention also provides a method to determine AGT activity, which comprises: a) AGT, b) an AGT binder carrying a radioactive molecule which is transferred to AGT, and Scintillation Proximity Assay (SPA) bead that binds AGT directly or indirectly (FIG. 4). In a further embodiment, the AGT binder is radioactive-labeled EX or AP.
The invention provides a method to determine AGT activity, comprising of AGT and an AGT binder carrying a chemical moiety which is transferred to AGT and the chemical moiety transferred to AGT is detected by streptavidin or an antibody.
This invention provides AGTDs which are not previously known.
This invention also provides a kit with a compartment containing AGTD.
This invention will be better understood from the examples which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXAMPLE 1

Scintillation Proximity Assay (SPA)

SPA beads are microscopic beads contain a scintillant that can be excite by radioactive signals to emit light. This excitation event occurs when radiolabeled molecules of interest are bound to the surface of the bead, either directly or indirectly (see FIG. 5); the light emitted can be detected with a scintillation counter.
Preparation of reagents. EX, labeled with 3[H] at various positions at the guanine moiety is used as the AGT binder. The AGT-specific monoclonal antibody (clone MT 3.1) (NeoMarkers, Fremont, Calif.) is used to capture AGT. SPA beads coated with anti-mouse antibody is used to bind the MT3.1 anti-AGT antibody. The guanine moiety containing 3[H] is transferred from the AGT binder to anti-AGT antibody and subsequently is captured by SPA beads.
Assay. Samples containing AGT, undiluted or diluted up to 100×, is added to a buffer containing a) 3[H]EX (1 fmol to 100 nmol), anti-AGT antibody (MT 3.1, 1 ng to 1 ug), and anti-mouse SPA bead (e.g. antimouse YSi bead, 1 ug to 10 mg, Amershan Bioscience). SPA beads coated with Protein A or Protein G can also be used. The solution is incubated for 15 to 60 minutes and radioactivity is determined with a scintillation counter. AGT activity is presented as dpm per mg protein. A précised AGT unit is determined by using 3[H]EX standard for constructing a standard curve. In this case, AGT activity is defined as fmol EX per mg protein. AGT activity can also be expressed as per DNA or cell number basis. An alternative method is to use biotin labeled anti-AGT antibody and streptavidin coated SPA beads.
EX can also be labeled with other radioactive isotopes or at other positions.

EXAMPLE 2

Immunoassay

This assay is based on using two antibodies or one antibody and streptavidin; one captures AGT and the other detects the chemical moiety transferred to AGT.
Preparation of reagents. The AGT-specific monoclonal antibody (clone MT 3.1) (NeoMarkers, Fremont, Calif.) is used to coat a 96-well plate to capture AGT. Streptavidin-conjugated peroxidase is used to detect the chemical moiety transferred to AGT.
Assay. This assay is based on a sandwich Elisa assay (Chapter 14, Antibodies, A laboratory Manual, Harlow and Lane, Cold Spring Harbor Laboratory, 1988). Samples containing AGT, undiluted or diluted up to 1000×, is added to a buffer containing biotin-conjugated EX (1 fmol to 100 nmol). The solution is incubated for 15 to 60 minutes; the incubation is stopped by the addition of a buffer with or without a detergent (e.g. 0.1% SDS or 0.1% NP40). The solution is added to the plate that coated with anti-AGT antibody and further incubated for 15 to 60 minutes. The plate is washed three times with a buffer containing a mild detergent. Streptavidin-conjugated peroxidase, at various dilution is added to the well and incubated for 15 to 60 minutes. The amount of biotin-conjugated EX bound to the AGT is determined by standard Elisa methods. AGT activity is presented as O.D. per mg protein. A précised AGT unit is determined by using biotin-conjugated EX standard for constructing a standard curve. In this case, AGT activity is defined as fmol EX per mg protein. AGT activity can also be expressed as per DNA or cell number basis.

EXAMPLE 3

Fluorescence Assay

The chemical moiety transferred from AGT binder to AGT contains a fluorophore (e.g. fluorescein, Texas red; Handbook of fluorescent probes and research products (P.62 and P15, Haugland, 9^thed., Molecular Probes, Eugene, Oreg.).
Preparation of the AGTD. A fluorescein molecule (Molecular Probe) is used to conjugate to the 8- or 9-position of the guanine moiety of EX (FIG. 3).
Assay. Samples containing AGT, undiluted or diluted up to 1000×, is added to the AGTD, at concentrations from 1 fmol/mg protein to 10000 fmol/mg protein. Molar ratio of AGT to AGTD is ranging from 1 to 1000, preferably from 5 to 200. AGT is incubated with AGTD in a buffer that maximize AGT activity. AGT activity is determined with a fluorescence spectrophotometer. For fluorescein, the excitation and emission wavelengths are 494 nm and 518 nm, respectively. AGT activity is presented as fluorescence unit per mg protein. A précised AGT unit is determined by using EX conjugated with fluorescein as standard for constructing a standard curve. In this case, AGT activity is defined as fmol EX per mg protein. AGT activity can also be expressed as per DNA or cell number basis.
Other detecting method such as fluorescence polarization or time-resolved fluorescence spectroscopy can also be used.

Claims

1. A method to determine AGT activity, comprising AGT and an AGT binder carrying a signaling molecule which is transferred to AGT.

2. The method according to claim 1 in which the AGT binder is an inhibitor of AGT.

3. The method according to claim 1 in which the AGT binder is an activator of AGT.

4. The method according to claim 1 in which the AGT binder is EX.

5. The method according to claim 1 in which the AGT binder is an oligonucleotide containing EX.

6. The method according to claim 1 in which the signal molecule is a fluorophore.

7. The method according to claim 1 in which the signal molecule is biotin.

8. A method to determine AGT activity, comprising: a) AGT, b) an AGT binder carrying a radioactive molecule which is transferred to AGT, and SPA bead that binds AGT directly or indirectly.

9. The method according to claim 8 in which the AGT binder is radioactive-labeled EX.

10. The method according to claim 1, set forth in FIG. 1.

11. A method to determine AGT activity, comprising of AGT and an AGT binder carrying a chemical moiety which is transferred to AGT and the chemical moiety transferred to AGT is detected by streptavidin.

12. The Scintillation Proximity Assay for AGT, set forth in FIG. 5.

13. An AGT binder, not previously known.

14. An AGT binder, set forth in FIG. 3 or 4.

15. A compound which binds to AGT, comprises an AGT binder and biotin.

16. The compound according to claim 15 wherein the AGT binder is EX.

17. A composition comprising the compound of claim 15 or 16.